On the subject of screening, an article in JAMA concludes ‘that annual screening for ovarian cancer as performed in the PLCO trial with simultaneous CA125 and transvaginal ultrasound does not reduce disease specific mortality in women at average risk for ovarian cancer but does increase invasive medical procedures and associated harms’. Effect of screening on Ovarian Cancer Mortality – The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomised Controlled Trial.
Saundra S Buys et al.JAMA.2011;305(22): 2295-2303
And on screening and over diagnosis, a commentary in Archives of Internal Medicine discusses the increasingly common phenomenon of pseudodisease Pseudodisease, the Next Great Epidemic in Coronary Atherosclerosis? Michael S. Lauer, MD Arch Intern Med. Published online May 23, 2011. doi:10.1001/archinternmed.2011.205 – a condition that would never have become clinically significant if it hadn’t been detected by a screening test. Pseudodisease can regress spontaneously, remain permanently subclinical, or progress so slowly that another disease kills the patient first. In any case, the patient derives no benefit from the diagnosis.
Nothing Personal: Disturbing Undercurrents in Cancer Care
Used in medical education.
Includes referenced discussion sections for evidence-based practice.
- Medical Journalists' Association Open Book Award
"A landmark for the patient voice"
- Macmillan Cancer Support
"A remarkable book... essential reading for all who deal with cancer patients - health professionals, politicians, health service developers, carers and, of course, patients themselves... will surely inspire change."
- Professor Karol Sikora in his foreword.